Demand for Vaccines to Exceed $14 Billion in 2014

Demand for vaccines in the US will grow 5.6 percent annually to $14.2 billion in 2014.  The US vaccines market experienced meteoric growth between 2004 and 2009.  Ongoing introduction of new products to prevent or to treat complex human diseases, such as cancer, will continue to advance vaccines sales.  This growth comes as a result of the introduction of significant new products and substantial new public health recommendations for adult and adolescent vaccines to address a wide range of diseases.  Also at play has been public response to the threat of a pandemic outbreak of H1N1 influenza.  New technologies and applications have rejuvenated research efforts to develop products, and an industry that was once highly concentrated is now seeing the entry of new players, from small, research-based firms to established companies.  These and other trends, including market share and product segmentation, are presented in US Vaccines, a new study from The Freedonia Group, Inc., a Cleveland-based industry market research firm.

Pediatric vaccines demand will exceed $4.9 billion in 2014 and will continue to grow, although not at the pace of demand for adult and adolescent vaccines.  While patents are expiring for vaccines that have long been used against common childhood diseases, new patented combination vaccines are being introduced that reduce the number of injections and protect against wider arrays of diseases.   

With annual shots recommended for individuals of all ages and new formulations extending product availability, seasonal influenza vaccines will generate strong growth opportunities.  Continued public health concern about pandemic influenza outbreaks has spurred research into better and faster methods of production for seasonal and pandemic flu vaccines, as well as into the possibility of a universal influenza vaccine to protect against a wide array of strains of the virus, including pandemic strains.  The market for pandemic flu vaccines fluctuates with disease outbreaks (with a particularly high year in 2009), but the demand for annual seasonal flu vaccines continues to grow, and could expand significantly with the introduction of a new universal influenza product.  

Demand for animal vaccines is forecast to expand 4.7 percent annually to $2.0 billion in 2014.  An increasing focus on food safety, the widening availability of insurance coverage for pet health care and new product introductions will promote growth.  Continuing advances in biotechnology will broaden the range of disease targets adaptable to animal vaccines. 

The Freedonia Group is a leading international business research company, founded in 1985, that publishes more than 100 industry research studies annually. This industry analysis provides an unbiased outlook and a reliable assessment of an industry and includes product segmentation and demand forecasts, industry trends, demand history, threats and opportunities, competitive strategies, market share determinations and company profiles.